Abstract:Velo-cardio-facial (VCFS) or Shprintzen syndrome is associated with deletions in a region of chromosome 22q11.2 also deleted in DiGeorge anomaly and some forms of congenital heart disease. Due to the variability of phenotype, the evaluation of the incidence of deletions has been hampered by uncertainty of diagnosis. In this study, 54 patients were diagnosed with VCFS by a single group of clinicians using homogeneous clinical criteria independent of the deletion status. Cell lines of these patients were establi… Show more
“…Our results showed that the majority of the 44 adults with 22q11DS studied shared a common 3.1 Mb hemizygous deletion of 22q11.2, consistent with the literature (Carlson et al 1997;Kurahashi et al 1997;Lindsay et al 1995;Saitta et al 2004). We refined the proximal breakpoint location to a ~250 Kb segment between USP18 and PRODH, and the distal breakpoint to a ~350 Kb segment between D22S936 and HIC2.…”
Section: Common Deletion Variants and Recurrent Breakpoint Regionssupporting
confidence: 92%
“…1), with the exception of the short nested 1.4 Mb deletion (ID 24), which had a distal breakpoint in a ~100 Kb segment between ARVCF and RANBP1. This deletion appears similar to the 1.5 Mb deletion previously described (Carlson et al 1997;Kurahashi et al 1997;Lindsay et al 1995;Saitta et al 2004), with breakpoints between D22S933 and ZNF74 (~706 Kb). The distal deletion breakpoint of these proximal nested deletions is commonly believed to be in LCR-B (Saitta et al 2004), although this would not appear to be the case for the 1.4 Mb deletion we found (Fig.…”
Section: Common Deletion Variants and Recurrent Breakpoint Regionssupporting
confidence: 82%
“…In other microdeletion syndromes such as Williams syndrome, some aspects of the phenotype appear related to the length of the deletion (Stock et al 2003). In contrast, most studies of 22q11DS have found no evidence for such an association (Carlson et al 1997;Kurahashi et al 1997;Lindsay et al 1995;Saitta et al 2004). Some recent studies have reported possible genotype-phenotype correlations, but these were based on small samples of patients with uncommon deletions and congenital phenotypic features (Bartsch et al 2003;Rauch et al 2005).…”
22q11 Deletion syndrome (22q11DS) is a common microdeletion syndrome with variable expression, including congenital and later onset conditions such as schizophrenia. Most studies indicate that expression does not appear to be related to length of the deletion but there is limited information on the endpoints of even the common deletion breakpoint regions in adults. We used a real-time quantitative PCR (qPCR) approach to fine map 22q11.2 deletions in 44 adults with 22q11DS, 22 with schizophrenia (SZ; 12 M, 10 F; mean age 35.7 SD 8.0 years) and 22 with no history of psychosis (NP; 8 M, 14 F; mean age 27.1 SD 8.6 years). QPCR data were consistent with clinical FISH results using the TUPLE1 or N25 probes. Two subjects (one SZ, one NP) negative for clinical FISH had atypical 22q11.2 deletions confirmed by FISH using the RP11-138C22 probe. Most (n = 34; 18 SZ, 16 NP) subjects shared a common 3 Mb hemizygous 22q11.2 deletion. However, eight subjects showed breakpoint variability: a more telomeric proximal breakpoint (n = 2), or more centromeric (n = 3) or more telomeric distal breakpoint (n = 3). One NP subject had a proximal nested 1.4 Mb deletion. COMT and TBX1 were deleted in all 44 subjects, and PRODH in 40 subjects (19 SZ, 21 NP). The results delineate proximal and distal breakpoint variants in 22q11DS. Neither deletion extent nor PRODH haploinsufficiency appeared to explain the clinical expression of schizophrenia in the present study. Further studies are needed to elucidate the molecular basis of schizophrenia and clinical heterogeneity in 22q11DS.
“…Our results showed that the majority of the 44 adults with 22q11DS studied shared a common 3.1 Mb hemizygous deletion of 22q11.2, consistent with the literature (Carlson et al 1997;Kurahashi et al 1997;Lindsay et al 1995;Saitta et al 2004). We refined the proximal breakpoint location to a ~250 Kb segment between USP18 and PRODH, and the distal breakpoint to a ~350 Kb segment between D22S936 and HIC2.…”
Section: Common Deletion Variants and Recurrent Breakpoint Regionssupporting
confidence: 92%
“…1), with the exception of the short nested 1.4 Mb deletion (ID 24), which had a distal breakpoint in a ~100 Kb segment between ARVCF and RANBP1. This deletion appears similar to the 1.5 Mb deletion previously described (Carlson et al 1997;Kurahashi et al 1997;Lindsay et al 1995;Saitta et al 2004), with breakpoints between D22S933 and ZNF74 (~706 Kb). The distal deletion breakpoint of these proximal nested deletions is commonly believed to be in LCR-B (Saitta et al 2004), although this would not appear to be the case for the 1.4 Mb deletion we found (Fig.…”
Section: Common Deletion Variants and Recurrent Breakpoint Regionssupporting
confidence: 82%
“…In other microdeletion syndromes such as Williams syndrome, some aspects of the phenotype appear related to the length of the deletion (Stock et al 2003). In contrast, most studies of 22q11DS have found no evidence for such an association (Carlson et al 1997;Kurahashi et al 1997;Lindsay et al 1995;Saitta et al 2004). Some recent studies have reported possible genotype-phenotype correlations, but these were based on small samples of patients with uncommon deletions and congenital phenotypic features (Bartsch et al 2003;Rauch et al 2005).…”
22q11 Deletion syndrome (22q11DS) is a common microdeletion syndrome with variable expression, including congenital and later onset conditions such as schizophrenia. Most studies indicate that expression does not appear to be related to length of the deletion but there is limited information on the endpoints of even the common deletion breakpoint regions in adults. We used a real-time quantitative PCR (qPCR) approach to fine map 22q11.2 deletions in 44 adults with 22q11DS, 22 with schizophrenia (SZ; 12 M, 10 F; mean age 35.7 SD 8.0 years) and 22 with no history of psychosis (NP; 8 M, 14 F; mean age 27.1 SD 8.6 years). QPCR data were consistent with clinical FISH results using the TUPLE1 or N25 probes. Two subjects (one SZ, one NP) negative for clinical FISH had atypical 22q11.2 deletions confirmed by FISH using the RP11-138C22 probe. Most (n = 34; 18 SZ, 16 NP) subjects shared a common 3 Mb hemizygous 22q11.2 deletion. However, eight subjects showed breakpoint variability: a more telomeric proximal breakpoint (n = 2), or more centromeric (n = 3) or more telomeric distal breakpoint (n = 3). One NP subject had a proximal nested 1.4 Mb deletion. COMT and TBX1 were deleted in all 44 subjects, and PRODH in 40 subjects (19 SZ, 21 NP). The results delineate proximal and distal breakpoint variants in 22q11DS. Neither deletion extent nor PRODH haploinsufficiency appeared to explain the clinical expression of schizophrenia in the present study. Further studies are needed to elucidate the molecular basis of schizophrenia and clinical heterogeneity in 22q11DS.
“…Among them was the anonymous genomic sequence D22S1660, which was derived from cosmid sc11.1. FISH experiments using this cosmid as a probe demonstrated that the region was duplicated on 22q11 and deleted in most patients with VCFS/DGS Lindsay et al 1993Lindsay et al , 1995. We determined that the duplicated region was demarcated by the markers 444P24Sp6 and D22S1660 and included the genes for DGCR6 and PRODH (proline dehydrogenase) ( Fig.…”
Section: Resultsmentioning
confidence: 98%
“…The FISH mapping revealed that two loci were present on 22q11, named sc11.1a (centromeric) and sc11.1b (telomeric), and were situated 1-2 Mb apart . Both loci were shown to be deleted in VCFS/DGS patients with the 3 Mb and 1.5 Mb deletions and therefore in most patients with VCFS/DGS (Lindsay et al , 1995.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.